Amphastar Pharmaceuticals to Quadruple U.S. Manufacturing Capacity at Rancho Cucamonga Headquarters

Reuters

Jul 15

<a href="https://laohu8.com/S/AMPH">Amphastar Pharmaceuticals</a> to Quadruple U.S. Manufacturing Capacity at Rancho Cucamonga Headquarters

Amphastar Pharmaceuticals Inc. has announced a significant expansion of its U.S. manufacturing operations at its Rancho Cucamonga headquarters. The bio-pharmaceutical company, known for its complex generic and proprietary injectable, inhalation, and intranasal products, plans to quadruple its production capacity over the next three to five years. This strategic initiative marks the largest investment in domestic infrastructure in Amphastar's history and aims to enhance supply chain resilience. The expansion will include a state-of-the-art production plant and advanced technologies, creating new jobs in research and development, engineering, manufacturing, and quality operations. Amphastar's commitment to domestic manufacturing is underscored by its focus on producing essential medicines in the United States.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amphastar Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1048521) on July 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2551359651"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2551359651\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2551359651?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-15 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551359651","market":"us","top_or_hot":-1,"title":"Amphastar Pharmaceuticals to Quadruple U.S. Manufacturing Capacity at Rancho Cucamonga Headquarters","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AMPH\">Amphastar Pharmaceuticals</a> to Quadruple U.S. Manufacturing Capacity at Rancho Cucamonga Headquarters\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Amphastar Pharmaceuticals Inc. has announced a significant expansion of its U.S. manufacturing operations at its Rancho Cucamonga headquarters. The bio-pharmaceutical company, known for its complex generic and proprietary injectable, inhalation, and intranasal products, plans to quadruple its production capacity over the next three to five years. This strategic initiative marks the largest investment in domestic infrastructure in Amphastar's history and aims to enhance supply chain resilience. The expansion will include a state-of-the-art production plant and advanced technologies, creating new jobs in research and development, engineering, manufacturing, and quality operations. Amphastar's commitment to domestic manufacturing is underscored by its focus on producing essential medicines in the United States.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amphastar Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1048521) on July 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amphastar Pharmaceuticals to Quadruple U.S. Manufacturing Capacity at Rancho Cucamonga Headquarters</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmphastar Pharmaceuticals to Quadruple U.S. Manufacturing Capacity at Rancho Cucamonga Headquarters\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-15 04:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AMPH\">Amphastar Pharmaceuticals</a> to Quadruple U.S. Manufacturing Capacity at Rancho Cucamonga Headquarters\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Amphastar Pharmaceuticals Inc. has announced a significant expansion of its U.S. manufacturing operations at its Rancho Cucamonga headquarters. The bio-pharmaceutical company, known for its complex generic and proprietary injectable, inhalation, and intranasal products, plans to quadruple its production capacity over the next three to five years. This strategic initiative marks the largest investment in domestic infrastructure in Amphastar's history and aims to enhance supply chain resilience. The expansion will include a state-of-the-art production plant and advanced technologies, creating new jobs in research and development, engineering, manufacturing, and quality operations. Amphastar's commitment to domestic manufacturing is underscored by its focus on producing essential medicines in the United States.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amphastar Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1048521) on July 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4557","symbol_name":"大麻股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nNDL4gTzCf:1","article_id":"2551359651","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551359651","pubTimestamp":1752523522,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Amphastar Pharmaceuticals Inc. has announced a significant expansion of its U.S. manufacturing operations at its Rancho Cucamonga headquarters. The bio-pharmaceutical company, known for its complex generic and proprietary injectable, inhalation, and intranasal products, plans to quadruple its production capacity over the next three to five years. This strategic initiative marks the largest investment in domestic infrastructure in Amphastar's history and aims to enhance supply chain resilience. The expansion will include a state-of-the-art production plant and advanced technologies, creating new jobs in research and development, engineering, manufacturing, and quality operations. Amphastar's commitment to domestic manufacturing is underscored by its focus on producing essential medicines in the United States.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gene","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4557":"大麻股","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4007":"制药","AMPH":"Amphastar Pharmaceuticals"},"translate_title":"Amphastar Pharmaceuticals将把库卡蒙加牧场总部的美国产能提高四倍","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMPH":0.9},"content_text":"Amphastar Pharmaceuticals to Quadruple U.S. Manufacturing Capacity at Rancho Cucamonga Headquarters\n    \n\n        Amphastar Pharmaceuticals Inc. has announced a significant expansion of its U.S. manufacturing operations at its Rancho Cucamonga headquarters. The bio-pharmaceutical company, known for its complex generic and proprietary injectable, inhalation, and intranasal products, plans to quadruple its production capacity over the next three to five years. This strategic initiative marks the largest investment in domestic infrastructure in Amphastar's history and aims to enhance supply chain resilience. The expansion will include a state-of-the-art production plant and advanced technologies, creating new jobs in research and development, engineering, manufacturing, and quality operations. Amphastar's commitment to domestic manufacturing is underscored by its focus on producing essential medicines in the United States.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amphastar Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1048521) on July 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}